L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.04 NOK 0.8%
Market Cap: 344m NOK

EV/EBIT
Enterprise Value to EBIT

-3.7
Current
-5.7
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3.7
=
Enterprise Value
302.6m NOK
/
EBIT
-82.8m NOK
Market Cap EV/EBIT
NO
Lytix Biopharma AS
OSE:LYTIX
344m NOK -3.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -209 183.8
US
Abbvie Inc
NYSE:ABBV
369.9B USD 25.7
US
Amgen Inc
NASDAQ:AMGN
167.3B USD 29.2
US
Gilead Sciences Inc
NASDAQ:GILD
139.6B USD 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.6B USD 26.6
US
Epizyme Inc
F:EPE
94.1B EUR -519.7
AU
CSL Ltd
ASX:CSL
121.3B AUD 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.5B USD 11.3
US
Seagen Inc
F:SGT
39.3B EUR -55.1
NL
argenx SE
XBRU:ARGX
32.6B EUR -2 297.1
EBIT Growth EV/EBIT to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBIT: 21.4
Negative Multiple: -3.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 183.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.7
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.2
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 297.1 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-2.4
2-Years Forward
EV/EBIT
-20.8
3-Years Forward
EV/EBIT
N/A